Braidwell LP Reduces Position in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Braidwell LP reduced its stake in Kiniksa Pharmaceuticals International by 43.1%, selling 1,489,538 shares during the first quarter and now holds 1.5% of the company.
• Several investment firms, including Vanguard Group and Millennium Management, increased their holdings in Kiniksa Pharmaceuticals, indicating growing institutional interest in the stock.
• Analysts have set price targets for Kiniksa, with Jefferies Financial Group raising its target from $45.00 to $54.00, while research analysts maintain an average rating of "Buy" for the stock.

Braidwell LP cut its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 43.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,962,909 shares of the company's stock after selling 1,489,538 shares during the quarter. Kiniksa Pharmaceuticals International comprises approximately 1.5% of Braidwell LP's investment portfolio, making the stock its 25th biggest position. Braidwell LP owned 2.69% of Kiniksa Pharmaceuticals International worth $43,596,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of KNSA. Wells Fargo & Company MN lifted its stake in Kiniksa Pharmaceuticals International by 54.7% during the 4th quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock worth $417,000 after acquiring an additional 7,463 shares in the last quarter. Barclays PLC lifted its stake in Kiniksa Pharmaceuticals International by 11.2% during the 4th quarter. Barclays PLC now owns 71,896 shares of the company's stock worth $1,423,000 after acquiring an additional 7,267 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Kiniksa Pharmaceuticals International by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock worth $15,262,000 after acquiring an additional 29,300 shares in the last quarter. MetLife Investment Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock worth $457,000 after acquiring an additional 1,374 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Kiniksa Pharmaceuticals International by 117.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after acquiring an additional 4,575 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on KNSA shares. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 30th. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA traded up $0.20 during mid-day trading on Friday, reaching $35.71. The company's stock had a trading volume of 328,234 shares, compared to its average volume of 429,216. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $35.84. The stock has a market cap of $2.65 billion, a PE ratio of 892.97 and a beta of 0.20. The company's 50 day moving average is $30.95 and its 200 day moving average is $26.49.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Eben Tessari sold 138,614 shares of the stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total value of $4,601,984.80. Following the transaction, the chief operating officer owned 49,915 shares in the company, valued at approximately $1,657,178. This represents a 73.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Michael R. Megna sold 17,000 shares of the stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $32.35, for a total value of $549,950.00. Following the completion of the transaction, the chief accounting officer owned 33,041 shares in the company, valued at approximately $1,068,876.35. The trade was a 33.97% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 558,403 shares of company stock worth $18,078,671. 53.48% of the stock is currently owned by company insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.